Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Wegovy is available by prescription
Key Takeaways Foundayo (orforglipron) is the first oral GLP-1 receptor agonist that can be taken any time of day without food or water restrictions FDA approved April 1, 2026 for chronic weight management Average weight loss in the ATTAIN-1 trial was 11.2% at 72 weeks at the highest dose less than injectable Wegovy (14.9%) or Zepbound (20.2%) Its small-molecule structure allows consistent absorption regardless of what is in the stomach Side effect profile is similar to other GLP-1 medications primarily gastrointestinal Starting cost is approximately $25/month with commercial insurance + Lilly savings card, $149/month self-pay for the lowest dose Best suited for patients with needle aversion, complicated schedules, or those who struggled with oral Wegovys fasting requirements Not recommended for patients already responding well to injectable GLP-1s Cannot be combined with other GLP-1 medications References Eli Lilly and Company
Specifically, the phase of preconception where so many healthcare providers emphasize the importance of weight loss but not nutrient gain
Horm Res Paediatr 78(1):5966
Yes, but only by a DEA-registered prescriber who complies with federal telemedicine rules and Nevada PMP requirements under NRS 453.162 and 453.164
